| Bioactivity | UP202-56 is an adenosine analogue, which is an adenosinergic agonist. |
| Target | Adenosine Receptor |
| Invitro | The effects of oral administration of UP202-56, an adenosine analogue, are assessed on carrageenan-induced spinal c-Fos protein expression and peripheral oedema. Oral UP202-56 (10, 30 or 50 mg/kg) dose-dependently reduces the number of carrageenan-induced c-Fos like immunoreactivity (c-Fos-LI) neurons (r=0.931. P<0.0001), with the highest dose of UP202-56 producing 72±4% reduction of the total number of carrageenan-induced spinal c-Fos-LI neurons, and 12±3% and 33±6% of reduction of control carrageenan oedema at paw and ankle levels, respectively. UP202-56 dose-dependently reduces the spinal c-Fos protein expression in carrageenan model of inflammatory pain[1]. UP202-56 is an adenosinergic agonist[2]. |
| Name | UP202-56 |
| CAS | 163838-04-8 |
| Formula | C34H38N6O4 |
| Molar Mass | 594.70 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Honoré P, et al. UP 202-56, an adenosine analogue, selectively acts via A1 receptors to significantly decrease noxiously-evoked spinal c-Fos protein expression. Pain. 1998 Apr;75(2-3):281-93. [2]. Camborde, Francois, et al. PHARMACEUTICAL COMBINATION WITH ANALGESIC ACTIVITY, CONTAINING AN ADENOSINERGIC AGONIST AND A COMPOUND SELECTED FROM OPIATES, BENZODIAZEPINES AND NMDA ANTAGONISTS. Patent Application WO/1999/029347. |